


What is claimed is:

1. Use of a compound of formula I,



wherein

W is O or S;

X is NR<sub>8</sub>;

Y is CR<sub>9</sub>R<sub>10</sub>-(CH<sub>2</sub>)<sub>n</sub> wherein

R<sub>9</sub> and R<sub>10</sub> are independently of each other hydrogen or lower alkyl, and  
n is an integer of from and including 0 to and including 3; or

Y is SO<sub>2</sub>;

R<sub>1</sub> is aryl;

R<sub>2</sub> is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with  
the exception that R<sub>2</sub> cannot represent 2-phthalimidyl, and in case of Y = SO<sub>2</sub> cannot  
represent 2,1,3-benzothiadiazol-4-yl;

any of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub>, independently of the other, is H or a substituent other than hy-  
drogen; and

R<sub>7</sub> and R<sub>8</sub>, independently of each other, are H or lower alkyl;

or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a  
pharmaceutical product for the treatment of a neoplastic disease which responds to an  
inhibition of the VEGF receptor tyrosine kinase activity.

2. Use of a compound of formula I, wherein the radicals and symbols have the meanings as defined in claim 1, or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of retinopathy or age-related macula degeneration.

3. A method for the treatment of a neoplastic disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity, which comprises administering a compound of formula I or a N-oxide or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined in claim 1, in a quantity effective against the said disease, to a warm-blooded animal requiring such treatment.

4. A method for the treatment of retinopathy or age-related macular degeneration, which comprises administering a compound of formula I or a N-oxide or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined in claim 1, in a quantity effective against said diseases, to a warm-blooded animal requiring such treatment.

5. A compound of formula I,

wherein

W is O or S;

X is NR<sub>8</sub>;

Y is CR<sub>9</sub>R<sub>10</sub>-(CH<sub>2</sub>)<sub>n</sub> wherein

R<sub>9</sub> and R<sub>10</sub> are independently of each other hydrogen or lower alkyl, and  
n is an integer of from and including 0 to and including 3; or

Y is SO<sub>2</sub>;

R<sub>1</sub> is aryl;

R<sub>2</sub> is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R<sub>2</sub> cannot represent 2-phthalimidyl, and in case of Y = SO<sub>2</sub> cannot represent 2,1,3-benzothiadiazol-4-yl;

any of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub>, independently of the other, is H or a substituent other than hydrogen; and

R<sub>7</sub> and R<sub>8</sub>, independently of each other, are H or lower alkyl;

with the exception of the compound of formula I wherein W is O, X is NR<sub>8</sub>, Y is CH<sub>2</sub>, R<sub>1</sub> is 4-chlorophenyl, R<sub>2</sub> is 2-pyridyl, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub> and R<sub>8</sub> are each H and R<sub>6</sub> is chloro; or a N-oxide or a pharmaceutically acceptable salt thereof.

6. A compound of formula I according to claim 5,

wherein

W is O or S;

X is NR<sub>8</sub>;

Y is CHR<sub>9</sub>-(CH<sub>2</sub>)<sub>n</sub> wherein

R<sub>9</sub> is hydrogen or lower alkyl, and

n is an integer of from and including 0 to and including 3; or

Y is SO<sub>2</sub>;

R<sub>1</sub> is aryl;

R<sub>2</sub> is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R<sub>2</sub> cannot represent 2-phthalimidyl, and in case of Y = SO<sub>2</sub> cannot represent 2,1,3-benzothiadiazol-4-yl;

any of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub>, independently of the other, is H or a substituent other than hydrogen; and

R<sub>7</sub> and R<sub>8</sub>, independently of each other, are H or lower alkyl;

with the exception of the compound of formula I wherein W is O, X is NR<sub>8</sub>, Y is CH<sub>2</sub>, R<sub>1</sub> is 4-chlorophenyl, R<sub>2</sub> is 2-pyridyl, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub> and R<sub>8</sub> are each H and R<sub>6</sub> is chloro; or a salt thereof.

7. A compound of formula I according to claim 5,

wherein

W is O or S;

X is NR<sub>8</sub>;

Y is CHR<sub>9</sub>-(CH<sub>2</sub>)<sub>n</sub> wherein

R<sub>9</sub> is H or lower alkyl, and



n is 0 to 3; or

Y is SO<sub>2</sub>;

R<sub>1</sub> is phenyl that is unsubstituted or substituted by up to three substituents selected from amino, mono- or disubstituted amino wherein the substituents are selected independently from lower alkyl, hydroxy-lower alkyl, phenyl-lower alkyl, lower alkanoyl, benzoyl and substituted benzoyl wherein the phenyl radical is substituted by one or two substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower-alkoxycarbonyl, lower alkanoyl and carbamoyl, and phenyl-lower alkoxy carbonyl wherein the phenyl radical is substituted by one or two substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower-alkoxycarbonyl, lower alkanoyl and

carbamoyl; lower alkyl; substituted lower alkyl where up to three substituents are present independently selected from the group containing halogen, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl and phenyl-lower alkoxycarbonyl; hydroxy, lower alkoxy; phenyl-lower alkoxy; phenoxy; halogen-lower alkoxy, lower alkanoyloxy; benzyloxy; lower alkoxycarbonyloxy; phenyl-lower alkoxycarbonyloxy; nitro; cyano; carboxy; lower alkoxycarbonyl; phenyl-lower alkoxycarbonyl; phenoxy carbonyl; lower alkyl carbonyl; carbamoyl; N-mono- or N,N-disubstituted carbamoyl that is substituted by one or two substituents independently selected from lower alkyl, phenyl-lower alkyl and hydroxy-lower alkyl, at the terminal nitrogen atom; amidino; guanidino; mercapto; sulfo; lower alkylthio; phenylthio; phenyl-lower alkylthio; lower alkylphenylthio; lower alkylsulfinyl; phenylsulfinyl; phenyl-lower alkylsulfinyl; lower alkylphenylsulfinyl; lower alkanesulfonyl; phenylsulfonyl; phenyl-lower alkylsulfonyl; lower alkylphenylsulfonyl; lower alkenyl; lower alkanoyl; halogen-lower alkylmercapto; halogen-lower alkylsulfonyl; dihydroxybora (-B(OH)<sub>2</sub>); and lower alkylene dioxy bound at adjacent C-atoms of the ring;

R<sub>2</sub> is imidazolyl, quinolyl, naphthyridinyl, or a moiety of the formula Ib or Ic



wherein

r is 0 to 2;

A, B, D, and E are, independently of one another, N or CH, with the stipulation that not more than 2 of these radicals are N; preferably; and

Q is lower alkyl, hydroxy, lower alkoxy, lower thioalkyl or halogen;

any of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub>, independently of the other, is H, fluorine or lower alkyl; and

R<sub>7</sub> and R<sub>8</sub>, independently of each other, are H or lower alkyl;

or a N-oxide or a pharmaceutically acceptable salt thereof.

8. A compound of formula I according to claim 5, wherein

W is O;

X is NR<sub>8</sub>;

Y is  $\text{CHR}_9-(\text{CH}_2)_n$  wherein

R<sub>9</sub> is H or methyl, and

n is 0;

or Y is SO<sub>2</sub>;

R<sub>1</sub> is phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl which is in each case either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen; lower alkyl; lower alkoxy; hydroxy; phenyl; phenoxy; halogen-lower alkoxy; halogen-lower alkyl; lower alkoxycarbonyl; N-lower alkyl carbamoyl; lower alkylsulfinyl; lower alkanesulfonyl; and lower alkoxycarbonyl lower alkyl;

R<sub>2</sub> is imidazolyl, quinolyl, naphthyridinyl, 2-methyl-pyridin-4-yl, 3-pyridyl or 4-pyridyl;

any of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub>, independently of the other, are H, methyl or chloro; or

R<sub>3</sub> and R<sub>4</sub> together represent methylene dioxy and R<sub>5</sub> and R<sub>6</sub>, independently of the other,

are H, methyl or chloro; and

R<sub>7</sub> and R<sub>8</sub>, independently of each other, are H, fluorine or methyl;

or a N-oxide or a pharmaceutically acceptable salt thereof.

9. A compound of formula I according to claim 5, wherein

W is O;

X is NR<sub>9</sub>;

Y is  $\text{CHR}_9-(\text{CH}_2)_n$  wherein

R<sub>9</sub> is H or methyl, and

n is 0;

or Y is SO<sub>2</sub>;

R<sub>1</sub> is phenyl which is either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen; lower alkyl; halogen-lower alkyl; lower alkylsulfinyl; and lower alkanesulfonyl;

R<sub>2</sub> is imidazolyl, quinolyl, naphthyridinyl, 2-methyl-pyridin-4-yl, 3-pyridyl or 4-pyridyl;

any of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub>, independently of the other, is H or methyl; and

R<sub>7</sub> and R<sub>8</sub>, independently of each other, are H or methyl;

or a N-oxide or a pharmaceutically acceptable salt thereof.

10. A compound of formula I according to claim 5, wherein

W is O;

X is NR<sub>8</sub>;

Y is CHR<sub>9</sub>-(CH<sub>2</sub>)<sub>n</sub> wherein

R<sub>9</sub> is H or methyl, and

n is 0;

or Y is SO<sub>2</sub>;

R<sub>1</sub> is phenyl which is either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen; lower alkyl; halogen-lower alkyl; lower alkylsulfinyl; and lower alkanesulfonyl;

R<sub>2</sub> is imidazolyl, quinolyl, 2-methyl-pyridin-4-yl or 4-pyridyl;

any of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub>, independently of the other, is H or methyl; and

R<sub>7</sub> and R<sub>8</sub>, independently of each other, are H or methyl;

or a salt thereof.

11. A compound of formula I according to claim 5, wherein

W is O;

X is NR<sub>8</sub>;

Y is CH<sub>2</sub>;

R<sub>1</sub> is phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl which is in each case either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen; lower alkyl; lower alkoxy; hydroxy; phenyl; phenoxy; halogen-lower alkoxy; lower alkoxycarbonyl; N-lower alkyl carbamoyl; and lower alkoxycarbonyl lower alkyl;

R<sub>2</sub> is 4-pyridyl;

any of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub>, independently of the other, are H, methyl or chloro; or

R<sub>3</sub> and R<sub>4</sub> together represent methylene dioxy and R<sub>5</sub> and R<sub>6</sub>, independently of the other, are H, methyl or chloro; and

R<sub>7</sub> and R<sub>8</sub> are H;

or a N-oxide or a pharmaceutically acceptable salt thereof.

12. A compound of formula I according to claim 5 selected from

2-[(4-pyridyl)methyl]amino-N-(4-trifluoromethylphenyl)benzamide;

2-[(4-pyridyl)methyl]amino-N-(4-chlorophenyl)benzamide;

2-[(4-pyridyl)methyl]amino-N-(4-methylphenyl)benzamide;

2-[(4-pyridyl)methyl]amino-N-(3-fluoro-4-methylphenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(4-chloro-3-trifluoromethylphenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(3-chloro-5-trifluoromethylphenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(4-methylphenyl)-6-methylbenzamide; and  
2-[(4-quinolyl)methyl]amino-N-(4-chloromethylphenyl)benzamide;  
or a pharmaceutically acceptable salt thereof.

13. A compound of formula I according to claim 5 selected from

2-[(4-pyridyl)methyl]amino-N-[3-fluoro-(4-trifluoromethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-phenylbenzamide;  
2-[(4-pyridyl)methyl]amino-N-[4-fluoro-3-(trifluoromethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3-fluoro-5-(trifluoromethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3,5-(bistrifluoromethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3,4-bis-(trifluoromethyl)phényl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3-methoxy-5-(trifluoromethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3-(1,1-dimethylethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-(3-cyanophenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-[(3-methylthio)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-(3-acetylaminophenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3-[(aminocarbonyl)amino]phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3-(dimethylamino)phenyl]benzamide;  
5-methoxy-2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
3-methyl-2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
4,5-difluoro-2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N'-methyl-N'-[3-(trifluoromethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[(3-methylsulphonyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[(3-methylsulphinylphenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[4-(1,1-dimethylethyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-(3-chlorophenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(3-bromophenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(3-methylphenyl)benzamide;

2-[(4-pyridyl)methyl]amino-N-(3-benzoylphenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3-(aminocarbonyl)phenyl]benzamide;  
2-[(3-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[(4-quinolinyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[(5-quinolinyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[(4-(2-methyl)pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[(4-(1,2-dihydro-2-oxo)pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[(4-quinolinyl)methyl]amino-N-(4-chlorophenyl)benzamide;  
2-[(2-imidazolyl)methyl]amino-N-(4-chlorophenyl)benzamide;  
2-[2-(4-pyridyl)ethyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[2-(3-pyridyl)ethyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[1-methyl-2-(3-pyridyl)ethyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide;  
2-[(1-oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide; and  
2-[(4-pyridyl)methyl]methylamino-N-[3-(trifluoromethyl)phenyl]benzamide;  
or a pharmaceutically acceptable salt thereof.

14. A compound of formula I according to claim 5 selected from

2-[(4-pyridyl)methyl]amino-N-(4-chloronaphthyl)benzamide;  
6-methyl-2-[(4-pyridyl)methyl]amino-N-(4-chlorophenyl)benzamide;  
6-chloro-2-[(4-pyridyl)methyl]amino-N-(4-chlorophenyl)benzamide;  
3,4-methylendioxy-6-[(4-pyridyl)methyl]amino-N-(4-chlorophenyl)benzamide;  
4,5-dimethyl-2-[(4-pyridyl)methyl]amino-N-(4-chlorophenyl)benzamide;  
5-chloro-2-[(4-pyridyl)methyl]amino-N-(4-n-propylphenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(4-n-propylphenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(7-hydroxynaphthyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(8-hydroxy-2-naphthyl)benzamide;  
4-chloro-2-[(4-pyridyl)methyl]amino-N-(4-chlorophenyl)benzamide;  
5-methyl-2-[(4-pyridyl)methyl]amino-N-(4-chlorophenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(5,6,7,8-tetrahydronaphthyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(4-biphenyl)benzamide;  
5-chloro-2-[(4-pyridyl)methyl]amino-N-(4-chlorophenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(naphthyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(2-naphthyl)benzamide;


2-[(4-pyridyl)methyl]amino-N-(4-methoxyphenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethoxy)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-(4-methoxy-2-naphthyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(3-bromo-2-naphthyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-[4-(isopropoxycarbonyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[4-(trifluoromethoxy)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-[4-(isopropylcarbamoyl)phenyl]benzamide;  
2-[(4-pyridyl)methyl]amino-N-(3-chloro-4-methylphenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-(2-methylphenyl)benzamide;  
2-[(4-pyridyl)methyl]amino-N-[3-(methoxycarbonylmethyl)phenyl]benzamide; and  
2-[(4-pyridyl)methyl]amino-N-(4-phenoxyphenyl)benzamide;  
or a pharmaceutically acceptable salt thereof.

15. A compound of formula I according to any one of claims 5 to 14, or a N-oxide thereof or a pharmaceutically acceptable salt of such a compound, for use in a method for the treatment of the human or animal body.

16. A pharmaceutical preparation, comprising a compound of formula I according to any one of claims 5 to 14, or a N-oxide or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier.

17. A process for the preparation of a compound of formula I according to claim 5, or a N-oxide or a pharmaceutically acceptable salt thereof, characterized in that

a) for the synthesis of a compound of the formula I wherein X represents NR<sub>8</sub>, where R<sub>8</sub> is hydrogen and Y represents CHR<sub>9</sub>-(CH<sub>2</sub>)<sub>n</sub>, each as indicated for a compound of formula I, and the remaining symbols W, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are as defined for a compound of the formula I, an aniline derivative of the formula II



wherein W, R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are as defined for a compound of the formula I, is reacted with a carbonyl compound of the formula III



wherein n, R<sub>2</sub> and R<sub>9</sub> are as defined for a compound of the formula I in the presence of a reducing agent; or

b) for the synthesis of a compound of the formula I wherein X is SO<sub>2</sub> and the remaining symbols R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, W and X are as defined for a compound of the formula I, an aniline derivative of the formula II as defined under process variante a) is reacted with an acid of the formula IVa




or a reactive derivative thereof; or with a compound of formula IVb,



wherein Hal' is chloro, bromo or iodo; or

c) for the synthesis of compounds of the formula I wherein X represents NR<sub>8</sub>, Y represents CR<sub>9</sub>R<sub>10</sub>-(CH<sub>2</sub>)<sub>n</sub> and the remaining symbols R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are as defined for a compound of the formula I, a halogen derivative of the formula V



wherein Hal represents iodine, bromine or chlorine and W, R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are as defined for a compound of the formula I, is reacted with an amine of the formula VI



wherein n, R<sub>2</sub>, R<sub>8</sub>, R<sub>9</sub> and R<sub>10</sub> are as defined for a compound of the formula I in the presence of an appropriate catalyst in an inert solvent in the presence of an aprotic base;

where the starting compounds defined in a), b) or c) may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible;

any protecting groups in a protected derivative of a compound of the formula I are removed; and, if so desired, an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.